Rilzabrutinib: Regulatory submission in Japan for immune thrombocytopenic purpura in H2 2025 (Sanofi) - Apr 24, 2025 - Q1 2025 Results: Regulatory decision in US/EU for immune thrombocytopenic purpura in H2 2025; Regulatory decision in China for immune thrombocytopenic purpura in 2026
China approval • EMA approval • FDA approval • Japan filing • Immune Thrombocytopenic Purpura • Immunology
|